Radius Health (NASDAQ:RDUS) had its price target cut by JPMorgan Chase & Co. from $59.00 to $52.00 in a report published on Friday. They currently have an overweight rating on the biopharmaceutical company’s stock.
A number of other analysts also recently commented on the stock. Bank of America dropped their price target on shares of Radius Health from $51.00 to $47.00 and set a buy rating on the stock in a research report on Wednesday, July 25th. Zacks Investment Research downgraded shares of Radius Health from a hold rating to a sell rating in a research report on Tuesday, October 9th. Jefferies Financial Group restated a hold rating and set a $25.00 price target on shares of Radius Health in a research report on Tuesday, August 7th. Cowen restated a hold rating on shares of Radius Health in a research report on Thursday, October 18th. Finally, BidaskClub upgraded shares of Radius Health from a strong sell rating to a sell rating in a research report on Tuesday, October 2nd. Three analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $48.14.
Shares of RDUS stock traded up $0.53 during midday trading on Friday, reaching $18.28. 1,318,592 shares of the company were exchanged, compared to its average volume of 856,089. Radius Health has a 12 month low of $15.74 and a 12 month high of $41.16. The company has a debt-to-equity ratio of 1.26, a quick ratio of 5.26 and a current ratio of 5.39.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.17. Radius Health had a negative net margin of 346.67% and a negative return on equity of 123.08%. The company had revenue of $27.70 million for the quarter, compared to the consensus estimate of $26.00 million. During the same period in the previous year, the firm earned ($1.31) EPS. Radius Health’s revenue was up 105.2% on a year-over-year basis. Equities analysts anticipate that Radius Health will post -5.34 earnings per share for the current fiscal year.
In other Radius Health news, major shareholder Growth N. V. Biotech bought 169,363 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were acquired at an average cost of $20.83 per share, for a total transaction of $3,527,831.29. Following the acquisition, the insider now directly owns 6,460,913 shares of the company’s stock, valued at $134,580,817.79. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Growth N. V. Biotech bought 60,000 shares of the company’s stock in a transaction that occurred on Monday, August 20th. The stock was acquired at an average price of $19.65 per share, for a total transaction of $1,179,000.00. Following the completion of the acquisition, the insider now directly owns 6,590,276 shares in the company, valued at $129,498,923.40. The disclosure for this purchase can be found here. Insiders purchased a total of 289,363 shares of company stock worth $6,070,631 over the last quarter. Insiders own 3.42% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc bought a new stake in shares of Radius Health in the 2nd quarter worth approximately $162,000. Xact Kapitalforvaltning AB bought a new stake in shares of Radius Health in the 1st quarter worth approximately $213,000. Cubist Systematic Strategies LLC raised its holdings in shares of Radius Health by 9,303.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,403 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 9,303 shares in the last quarter. Raymond James & Associates raised its holdings in shares of Radius Health by 15.0% during the second quarter. Raymond James & Associates now owns 18,766 shares of the biopharmaceutical company’s stock valued at $553,000 after acquiring an additional 2,449 shares during the period. Finally, Price Capital Management Inc. acquired a new stake in shares of Radius Health during the second quarter valued at approximately $674,000.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Further Reading: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.